What's Happening?
Axoft, a neurotechnology company based in Cambridge, has successfully raised $55 million in a Series A funding round led by C.P. Group Innovation. This funding will be utilized to expand global clinical trials, progress U.S. regulatory approval for its
implantable Brain-Computer Interfaces (iBCIs), and establish a GMP manufacturing facility in Cambridge, MA. Axoft's iBCIs use a proprietary material called Fleuron™, which is significantly softer than traditional materials, reducing tissue scarring and signal attenuation. The company has completed first-in-human clinical trials in 11 patients across various sites, including Mass General Brigham and The Panama Clinic. Fleuron™ is now commercially available for biomedical applications through a licensing agreement with Stanford University.
Why It's Important?
The development of Axoft's iBCIs represents a significant advancement in neurotechnology, addressing the material mismatch between the human brain and conventional implants. This breakthrough allows for long-term, high-density neural data capture, which is crucial for improving the standard of care for neurological disorders affecting millions worldwide. The funding will enable Axoft to transition from a research-focused entity to a global clinical and manufacturing powerhouse, potentially revolutionizing the treatment of conditions such as tumor mapping and disorders of consciousness. The availability of Fleuron™ to the broader biomedical community further positions Axoft as a key player in the neurotechnology ecosystem.
What's Next?
Axoft plans to aggressively pursue U.S. regulatory milestones while scaling its international clinical footprint. The establishment of a GMP facility in Cambridge will support the mass production of its iBCIs and proprietary materials, meeting the needs of clinical partners and commercial material customers. This expansion is supported by grant funding from the Massachusetts Manufacturing Innovation Initiative, underscoring the company's commitment to building a sustainable neurotech hub in New England.
